377 related articles for article (PubMed ID: 24309084)
1. Use of mTOR inhibitors in chronic heart transplant recipients with renal failure: calcineurin-inhibitors conversion or minimization?
Gonzalez-Vilchez F; Vazquez de Prada JA; Paniagua MJ; Gomez-Bueno M; Arizon JM; Almenar L; Roig E; Delgado J; Lambert JL; Perez-Villa F; Sanz-Julve ML; Crespo-Leiro M; Segovia J; Lopez-Granados A; Martinez-Dolz L; Mirabet S; Escribano P; Diaz-Molina B; Farrero M; Blasco T
Int J Cardiol; 2014 Jan; 171(1):15-23. PubMed ID: 24309084
[TBL] [Abstract][Full Text] [Related]
2. Renal function improvement after conversion to proliferation signal inhibitors during long-term follow-up in heart transplant recipients.
Kaplinsky E; González-Costello J; Manito N; Roca J; Barbosa MJ; Nebot M; Salazar-Mendiguchia J; Berdejo J; Mañas P; Miralles A; Cequier A
Transplant Proc; 2012 Nov; 44(9):2564-6. PubMed ID: 23146455
[TBL] [Abstract][Full Text] [Related]
3. Conversion of long-term kidney transplant recipients from calcineurin inhibitor therapy to everolimus: a randomized, multicenter, 24-month study.
Holdaas H; Rostaing L; Serón D; Cole E; Chapman J; Fellstrøm B; Strom EH; Jardine A; Midtvedt K; Machein U; Ulbricht B; Karpov A; O'Connell PJ;
Transplantation; 2011 Aug; 92(4):410-8. PubMed ID: 21697773
[TBL] [Abstract][Full Text] [Related]
4. Renal function preservation with the mTOR inhibitor, Everolimus, after lung transplant.
Schneer S; Kramer MR; Fox B; Rusanov V; Fruchter O; Rosengarten D; Bakal I; Medalion B; Raviv Y
Clin Transplant; 2014 Jun; 28(6):662-8. PubMed ID: 24738962
[TBL] [Abstract][Full Text] [Related]
5. mTOR inhibitor monotherapy. A good treatment choice in renal transplantation?
Franco-Esteve A; Tordera D; de la Sen ML; Jiménez L; Mas P; Muñoz C; Olivares J
Nefrologia; 2012; 32(5):631-8. PubMed ID: 23013949
[TBL] [Abstract][Full Text] [Related]
6. Long-Term Renal Function in Liver Transplant Recipients After Conversion From Calcineurin Inhibitors to mTOR Inhibitors.
Hüsing A; Schmidt M; Beckebaum S; Cicinnati VR; Koch R; Thölking G; Stella J; Heinzow H; Schmidt HH; Kabar I
Ann Transplant; 2015 Nov; 20():707-13. PubMed ID: 26608590
[TBL] [Abstract][Full Text] [Related]
7. Replacement of calcineurin-inhibitors with sirolimus as primary immunosuppression in stable cardiac transplant recipients.
Raichlin E; Khalpey Z; Kremers W; Frantz RP; Rodeheffer RJ; Clavell AL; Edwards BS; Kushwaha SS
Transplantation; 2007 Aug; 84(4):467-74. PubMed ID: 17713429
[TBL] [Abstract][Full Text] [Related]
8. Results of 4-year analysis of conversion from calcineurin inhibitors to mTOR inhibitors in renal transplant patients: single-center experience.
Sert M; Celik A; Kural K; Ersan S; Ataca P; Atila K; Cavdar C; Sifil A; Bora S; Gulay H; Camsari T
Ren Fail; 2011; 33(8):789-94. PubMed ID: 21787153
[TBL] [Abstract][Full Text] [Related]
9. Calcineurin inhibitor sparing regimens using m-target of rapamycin inhibitors: an opportunity to improve cardiovascular risk following kidney transplantation?
Zeier M; Van Der Giet M
Transpl Int; 2011 Jan; 24(1):30-42. PubMed ID: 20642495
[TBL] [Abstract][Full Text] [Related]
10. Steroid and calcineurin inhibitor-sparing protocols in kidney transplantation.
Helal I; Chan L
Transplant Proc; 2011 Mar; 43(2):472-7. PubMed ID: 21440737
[TBL] [Abstract][Full Text] [Related]
11. Rejection after conversion to a proliferation signal inhibitor in chronic heart transplantation.
González-Vílchez F; Vázquez de Prada JA; Paniagua MJ; Almenar L; Mirabet S; Gómez-Bueno M; Díaz-Molina B; Arizón JM; Delgado J; Pérez-Villa F; Crespo-Leiro MG; Martínez-Dolz L; Roig E; Segovia J; Lambert JL; Lopez-Granados A; Escribano P; Farrero M
Clin Transplant; 2013; 27(6):E649-58. PubMed ID: 24025040
[TBL] [Abstract][Full Text] [Related]
12. Clinical insights for cancer outcomes in renal transplant patients.
Alberú J
Transplant Proc; 2010 Nov; 42(9 Suppl):S36-40. PubMed ID: 21095450
[TBL] [Abstract][Full Text] [Related]
13. Calcineurin inhibitor minimization using sirolimus leads to improved renal function in pediatric heart transplant recipients.
Chinnock TJ; Shankel T; Deming D; Cutler D; Sahney S; Fitts J; Chinnock RE
Pediatr Transplant; 2011 Nov; 15(7):746-9. PubMed ID: 21883751
[TBL] [Abstract][Full Text] [Related]
14. Sirolimus in cardiac transplantation: use as a primary immunosuppressant in calcineurin inhibitor-induced nephrotoxicity.
Kushwaha SS; Khalpey Z; Frantz RP; Rodeheffer RJ; Clavell AL; Daly RC; McGregor CG; Edwards BS
J Heart Lung Transplant; 2005 Dec; 24(12):2129-36. PubMed ID: 16364861
[TBL] [Abstract][Full Text] [Related]
15. Long-term results in renal transplant patients with allograft dysfunction after switching from calcineurin inhibitors to sirolimus.
Bumbea V; Kamar N; Ribes D; Esposito L; Modesto A; Guitard J; Nasou G; Durand D; Rostaing L
Nephrol Dial Transplant; 2005 Nov; 20(11):2517-23. PubMed ID: 15985508
[TBL] [Abstract][Full Text] [Related]
16. Improvement in renal function after everolimus introduction and calcineurin inhibitor reduction in maintenance thoracic transplant recipients: the significance of baseline glomerular filtration rate.
Arora S; Gude E; Sigurdardottir V; Mortensen SA; Eiskjær H; Riise G; Mared L; Bjørtuft O; Ekmehag B; Jansson K; Simonsen S; Aukrust P; Solbu D; Iversen M; Gullestad L
J Heart Lung Transplant; 2012 Mar; 31(3):259-65. PubMed ID: 22333403
[TBL] [Abstract][Full Text] [Related]
17. Conversion from a calcineurin inhibitor to everolimus therapy in maintenance liver transplant recipients: a prospective, randomized, multicenter trial.
De Simone P; Metselaar HJ; Fischer L; Dumortier J; Boudjema K; Hardwigsen J; Rostaing L; De Carlis L; Saliba F; Nevens F
Liver Transpl; 2009 Oct; 15(10):1262-9. PubMed ID: 19790150
[TBL] [Abstract][Full Text] [Related]
18. Focus on mTOR inhibitors and tacrolimus in renal transplantation: pharmacokinetics, exposure-response relationships, and clinical outcomes.
Shihab F; Christians U; Smith L; Wellen JR; Kaplan B
Transpl Immunol; 2014 Jun; 31(1):22-32. PubMed ID: 24861504
[TBL] [Abstract][Full Text] [Related]
19. Clinical evidence on the use of anti-mTOR drugs in renal transplantation.
Hernández D; Martínez D; Gutiérrez E; López V; Gutiérrez C; García P; Cobelo C; Cabello M; Burgos D; Sola E; González-Molina M
Nefrologia; 2011; 31(1):27-34. PubMed ID: 21270910
[TBL] [Abstract][Full Text] [Related]
20. Treatment with everolimus is associated with a procoagulant state.
Baas MC; Gerdes VE; Ten Berge IJ; Heutinck KM; Florquin S; Meijers JC; Bemelman FJ
Thromb Res; 2013 Aug; 132(2):307-11. PubMed ID: 23906938
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]